by The Global Sanger Sequencing Market involves technological procedures for determining the order of deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) in biological samples. Sanger sequencing is based on the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. It helps analyze genetic variations in samples and identify cancer biomarkers, amongst other applications.
The Global Sanger Sequencing Market is estimated to be valued at US$ 10,130.6 Mn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Global Sanger Sequencing Market are Eurofins Scientific, CeMIA, Fasteris SA, GENEWIZ, GenHunter Corporation, GenScript, LGC Biosearch Technologies, Nucleics, Quintara Biosciences, SciGenom Labs Pvt. Ltd, StarSEQ GmbH, Thermo Fisher Scientific Inc., QIAGEN, Promega Corporation, and Source BioScience. The growing demand for Sanger sequencing from sectors like healthcare and biotechnology is facilitating the growth of the market. Sanger sequencing finds wide applications in DNA fingerprinting, genotyping, and linkage analysis studies and is hence witnessing increased adoption. Furthermore, expansion of Sanger sequencing companies across regions is expected to supplement the growth of the global market.
Market Key Trends
The emergence of next-generation sequencing (NGS) technologies and their rapid adoption is one of the key trends being witnessed in the global Sanger sequencing market. NGS offers higher throughput and lower turnaround times as compared to Sanger sequencing. Technologies like nanopore sequencing and single-molecule real-time sequencing are capable of sequencing entire human genomes in a single run at a much lower cost than Sanger sequencing. This has led to a decline in the demand for Sanger sequencing for whole genome sequencing. However, it is still useful for smaller targeted resequencing applications and finding variations in known disease genes.
Porter’s Analysis
Threat of new entrants: The global Sanger sequencing market is moderately difficult to enter due to the requirement of high capital investments and technical expertise.
Bargaining power of buyers: The bargaining power of buyers is moderate as Sanger sequencing is a niche technique and alternatives are available.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the availability of alternative suppliers in the market.
Threat of new substitutes: Next-generation sequencing is a major threat being a faster and low-cost substitute for Sanger sequencing.
Competitive rivalry: The competitive rivalry in the global Sanger sequencing market is high due to the presence of multiple international players.
Geographical Regions:
The value share of the global Sanger sequencing market is highly concentrated in North America. The region accounts for the largest market share of over 35% owing to ongoing technological advancements and investments in genomics and precision medicine.
Asia Pacific is expected to witness the fastest growth during the forecast period attributed to rising genome mapping initiatives, increasing research funding, and growing collaborations between research laboratories and sequencing companies in countries such as China and India. The market is witnessing rapid commercialization of clinical Sanger sequencing testing which is fueling market growth in the region.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research.
2. We have leveraged AI tools to mine information and compile it.
